Pacer Advisors’s Crescent Biopharma CBIO Stock Holding History

Pacer Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-42	Closed	-$60K	–	744
2018 Q3	$60K	Buy	+42	New	+$63.5K	﹤0.01%	1132

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Pacer Advisors's CBIO Position: Q4 2018 in Review

Pacer Advisors sold out of Crescent Biopharma (CBIO) in Q4 2018, closing a stake of 42 shares — an estimated $60K sold.

Pacer Advisors first reported a position in CBIO in Q3 2018 and held it in 1 quarter. The position peaked at $60K in Q3 2018. 81 funds tracked by Wall St. Rank hold CBIO as of Q4 2018.

Pacer Advisors reported no remaining Crescent Biopharma position as of Q4 2018 after selling out during the quarter.
Pacer Advisors sold 42 Crescent Biopharma shares in Q4 2018, an estimated $60K.
Pacer Advisors first reported a position in Crescent Biopharma in Q3 2018 and held it in 1 quarter.
Pacer Advisors's Crescent Biopharma position peaked at $60K in Q3 2018.
81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.